MX2020007501A - Metodos para tratar la enfermedad de farber. - Google Patents

Metodos para tratar la enfermedad de farber.

Info

Publication number
MX2020007501A
MX2020007501A MX2020007501A MX2020007501A MX2020007501A MX 2020007501 A MX2020007501 A MX 2020007501A MX 2020007501 A MX2020007501 A MX 2020007501A MX 2020007501 A MX2020007501 A MX 2020007501A MX 2020007501 A MX2020007501 A MX 2020007501A
Authority
MX
Mexico
Prior art keywords
methods
farber disease
treating farber
treating
disease
Prior art date
Application number
MX2020007501A
Other languages
English (en)
Inventor
Eric Gaukel
Brante Sampey
Original Assignee
Enzyvant Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzyvant Therapeutics Gmbh filed Critical Enzyvant Therapeutics Gmbh
Publication of MX2020007501A publication Critical patent/MX2020007501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos para tratar la enfermedad de Farber mediante el uso de dosis y perfiles farmacocinéticas particulares.
MX2020007501A 2018-02-02 2019-01-31 Metodos para tratar la enfermedad de farber. MX2020007501A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625763P 2018-02-02 2018-02-02
PCT/IB2019/000077 WO2019150192A1 (en) 2018-02-02 2019-01-31 Methods for treating farber disease

Publications (1)

Publication Number Publication Date
MX2020007501A true MX2020007501A (es) 2020-10-16

Family

ID=65951809

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007501A MX2020007501A (es) 2018-02-02 2019-01-31 Metodos para tratar la enfermedad de farber.
MX2025007132A MX2025007132A (es) 2018-02-02 2020-07-13 Metodos para tratar la enfermedad de farber

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025007132A MX2025007132A (es) 2018-02-02 2020-07-13 Metodos para tratar la enfermedad de farber

Country Status (15)

Country Link
US (2) US20190240298A1 (es)
EP (2) EP3746115A1 (es)
JP (3) JP2021512853A (es)
KR (2) KR20200118011A (es)
CN (1) CN112703010A (es)
AU (2) AU2019214519A1 (es)
BR (1) BR112020015003A2 (es)
CA (1) CA3088225A1 (es)
CL (1) CL2020001856A1 (es)
IL (2) IL312159A (es)
MX (2) MX2020007501A (es)
PH (1) PH12020551146A1 (es)
RU (1) RU2020118032A (es)
SG (1) SG11202006506TA (es)
WO (1) WO2019150192A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3568154B1 (en) * 2017-01-13 2023-07-12 Icahn School of Medicine at Mount Sinai Compositions and methods for treating farber disease
US20220088158A1 (en) * 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
US20220347276A1 (en) * 2019-09-11 2022-11-03 Icahn School Of Medicine At Mount Sinai Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840224C (en) * 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
CN112126634A (zh) * 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
AU2014226126B2 (en) * 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
CA3036672C (en) 2016-09-16 2021-08-24 Vilter Manufacturing Llc High suction pressure single screw compressor with thrust balancing load using shaft seal pressure and related methods
EP3568154B1 (en) 2017-01-13 2023-07-12 Icahn School of Medicine at Mount Sinai Compositions and methods for treating farber disease
WO2019060837A1 (en) * 2017-09-25 2019-03-28 Enzyvant Farber Gmbh PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE

Also Published As

Publication number Publication date
CN112703010A (zh) 2021-04-23
CL2020001856A1 (es) 2020-12-04
JP2023113809A (ja) 2023-08-16
AU2025202813A9 (en) 2026-03-05
KR20250016468A (ko) 2025-02-03
JP2025041867A (ja) 2025-03-26
WO2019150192A1 (en) 2019-08-08
US20230123505A1 (en) 2023-04-20
IL312159A (en) 2024-06-01
EP4556066A2 (en) 2025-05-21
EP4556066A3 (en) 2025-07-16
US20190240298A1 (en) 2019-08-08
IL276284A (en) 2020-09-30
BR112020015003A2 (pt) 2020-12-29
AU2025202813A1 (en) 2025-05-15
JP2021512853A (ja) 2021-05-20
RU2020118032A (ru) 2022-03-02
MX2025007132A (es) 2025-07-01
EP3746115A1 (en) 2020-12-09
PH12020551146A1 (en) 2021-06-28
AU2019214519A1 (en) 2020-06-18
KR20200118011A (ko) 2020-10-14
SG11202006506TA (en) 2020-08-28
CA3088225A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MX2024013018A (es) Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso
PH12016502453A1 (en) Heteroaryl compounds for kinase inhibition
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
EA201992781A1 (ru) Ингибиторы g12c kras и способы их применения
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
GB2541571A (en) Pharmaceutical compositions
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MX2020005446A (es) Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
HK1251567A1 (zh) 用於激酶抑制的杂芳基化合物
ZA201807438B (en) Methods of treating ocular conditions
IN2014MU00303A (es)
PH12020551146A1 (en) Methods for treating farber disease
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
ZA201703467B (en) Methods of treating ocular conditions
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
PH12020551193A1 (en) Certain chemical entities, compositions, and methods
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
NZ763986A (en) Heteroaryl compounds for kinase inhibition
HK40042326A (en) Methods for treating farber disease
EP3263103A4 (en) Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using said composition